Literature DB >> 9529416

New drug treatment for Alzheimer's disease: lessons for healthcare policy.

D Melzer1.   

Abstract

Entities:  

Keywords:  Aricept; Biomedical and Behavioral Research; Mental Health Therapies; National Health Service; Professional Patient Relationship

Mesh：

Substances：

Year:  1998        PMID： 9529416      PMCID： PMC1112729          DOI： 10.1136/bmj.316.7133.762

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  7 in total

Review 1.  Policy issues in the private health sector: examples from long-term care in the U.K.

Authors:  H P Bartlett; D R Phillips
Journal:  Soc Sci Med       Date:  1996-09       Impact factor: 4.634

2.  Research suppressed for seven years by drug company.

Authors:  J Wise
Journal:  BMJ       Date:  1997-04-19

3.  Drug treatments for Alzheimer's disease.

Authors:  C A Kelly; R J Harvey; H Cayton
Journal:  BMJ       Date:  1997-03-08

4.  Advertisements for donepezil (Aricept) in the BMJ. Local committee has declined to approve NHS hospital prescription of donepezil.

Authors:  N Wagner
Journal:  BMJ       Date:  1997-05-24

5.  Advertisements for donepezil (Aricept) in the BMJ. Advertisement suggests an unrealistic improvement in mental status.

Authors:  S Gray
Journal:  BMJ       Date:  1997-05-24

Review 6.  Technology assessment. Old, new, and needs-based.

Authors:  P Tugwell; C Sitthi-Amorn; A O'Connor; J Hatcher-Roberts; Y Bergevin; M Wolfson
Journal:  Int J Technol Assess Health Care       Date:  1995       Impact factor: 2.188

7.  The UK Community Care Act (1990) and the elderly.

Authors:  M Impallomeni; J Starr
Journal:  Lancet       Date:  1994-10-29       Impact factor: 79.321
  7 in total
  19 in total

1.  Effectiveness of rivastigmine in Alzheimer's disease. Participation in trials should be based on clinical uncertainty, not enforcement.

Authors:  R Bullock; P Passmore; D Wilkinson; R Howard; R Jones
Journal:  BMJ       Date:  2000-02-19

2.  Acetylcholinesterase inhibitors for Alzheimer's disease.

Authors:  L Flicker
Journal:  BMJ       Date:  1999-03-06

3.  Equity in the new NHS: hard lessons from implementing a local healthcare policy on donepezil.

Authors:  Y Doyle
Journal:  BMJ       Date:  2001-07-28

4.  New drugs with novel therapeutic characteristics. Have they been subject to randomized controlled trials?

Authors:  Joel Lexchin
Journal:  Can Fam Physician       Date:  2002-09       Impact factor: 3.275

5.  Neuropsychotherapeutics in the UK: what has been the impact of NICE on prescribing?

Authors:  Tom Walley
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

6.  New drug treatment for Alzheimer's disease. Doctors want to offer more than sympathy.

Authors:  T Dening; C Lawton
Journal:  BMJ       Date:  1998-10-03

7.  Effect of four medicinal plants on amyloid-β induced neurotoxicity in SH-SY5Y cells.

Authors:  Emanuel A Adewusi; Gerda Fouche; Vanessa Steenkamp
Journal:  Afr J Tradit Complement Altern Med       Date:  2013-05-16

Review 8.  Cost effectiveness of cholinesterase inhibitors in the treatment of Alzheimer's disease: a review with methodological considerations.

Authors:  Anders Wimo
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

9.  Comparative Study of White and Steamed Black Panax ginseng, P. quinquefolium, and P. notoginseng on Cholinesterase Inhibitory and Antioxidative Activity.

Authors:  Mi Ra Lee; Beom Sik Yun; Chang Keun Sung
Journal:  J Ginseng Res       Date:  2012-01       Impact factor: 6.060

10.  Comparative study of korean white, red, and black ginseng extract on cholinesterase inhibitory activity and cholinergic function.

Authors:  Mi Ra Lee; Beom Sik Yun; Oh Hyun In; Chang Keun Sung
Journal:  J Ginseng Res       Date:  2011-11       Impact factor: 6.060
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.